Increased need for thyroxine in women with hypothyroidism during estrogen therapy
Article Abstract:
Women with hypothyroidism who begin taking estrogen replacement therapy should have their thyroid hormones checked about 12 weeks later. Estrogen affects the concentration of thyroid hormones, so these women may need higher doses of thyroxine.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
Estrogen, thyroxine binding in serum, and thyroxine therapy
Article Abstract:
Women who are taking thyroid hormone may need to take a higher dose if they begin taking estrogen replacement therapy. This is necessary because estrogen increases the amount of thyroxine-binding globulin, a protein that normally binds to thyroid hormone.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
Therapy of hypothyroidism: when are changes needed?
Article Abstract:
Treatment options for people with hypothyroidism (inadequate production of thyroid hormone, which is important in many metabolic processes) are reviewed and evaluated. An article in the July 12, 1990 issue of The New England Journal of Medicine concluded that pregnant women with primary hypothyroidism needed more thyroid hormone (thyroxine) than they had been taking prior to pregnancy. In general, when blood levels of thyroid hormone fall, levels of thyrotropin (the hormone that stimulates its production) increase dramatically. Thyrotropin is made by cells in the pituitary gland that sense circulating levels of thyroid hormone and are very sensitive to small changes in hormone concentrations. Thus, measurement of thyrotropin levels is a good indicator of the efficacy of thyroxine therapy. Minor aberrations from the normal concentration are no cause for concern, except in cases such as pregnancy, where fetal and maternal health could be affected. Although the thyroid gland normally secretes both thyroxine and triiodothyronine, the only substance needed by hypothyroid people is thyroxine, since much of the triiodothyronine is made from thyroxine in non-thyroid tissues. Administration of extra quantities of this substance can throw off the body's physiological balance. Most hypothyroid adults need 100 micrograms of thyroxine daily, a lower dose than formerly recommended. Ideal doses can be calculated using new tests that allow very sensitive monitoring of thyrotropin levels. Patients who take thyroxine are often noncompliant, taking more when they feel they need it, or stopping treatment if all goes well. Dosage alteration may be required because of ongoing disease processes, or the administration of different hormones or drugs for treating other conditions. Age and body weight can affect the way thyroxine is cleared from the body; older adults need less than younger adults. Dose levels need careful consideration in patients with ischemic heart disease (where the blood supply to the heart is insufficient) or thyroid cancer. However, appropriate treatment of hypothyroidism is usually not difficult. (Consumer Summary produced by Reliance Medical Information, Inc.)
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1990
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Intrathecal baclofen for the treatment of dystonia in patients with reflex sympathetic dystrophy. Spinal cord stimulation in patients with chronic reflex sympathetic dystrophy
- Abstracts: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3
- Abstracts: Hemodynamic response to tibolone in reproductive and nonreproductive tissues in the sheep. Leptin in the ovine fetus correlates with fetal and placental size
- Abstracts: Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal Osteoporosis: A Randomized Controlled Trial
- Abstracts: Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial